The Neurogenic Orthostatic Hypotension (NOH) Market is expected to develop at a compound annual growth rate (CAGR) of 7.2%. In 2022, the market was estimated to be worth USD 376 million. Standing causes a large drop in blood pressure due to neurogenic orthostatic hypotension (NOH), a rare neurological condition affecting the autonomic nervous system. This may result in symptoms including fainting, dizziness, and falls.
The rising prevalence of NOH and the availability of efficient treatment options are projected to fuel consistent expansion in the NOH treatment market over the next several years. To some extent, however, market expansion may be hampered by the high expense of care and the scarcity of cutting-edge treatment choices in some areas. Furthermore, a barrier to market expansion may be the low level of knowledge about the illness among consumers and medical experts.
Get a Free Sample Copy of the Report – https://wemarketresearch.com/sample-request/neurogenic-orthostatic-hypotension-noh-market/1029
Regional Scope
- North America
- Europe
- APAC
- South America
- Middle East
- Africa
Key Company
- Sumitomo Pharmaceuticals
- Chelsea Therapeutics (Droxidopa)
- Shire PLC (ProAmatine®)
- NORTHERA® (Droxidopa)
Scope of the Report
This study provides history, present, and future analysis and estimates for the Neurogenic orthostatic hypotension (NOH) Market. The report’s market estimations are based on a comprehensive research approach. The research process used includes many channels of research, such as primary research, secondary research, and subject-related expert opinion. The market estimations are produced using the current market dynamics as well as many economic, social, and political aspects affecting the Seasonal Affective Disorder Market. The market data is also defined by numerous legislation, government investments, and increased R&D. The market projections take into account both positive and negative developments in the market.
Regional Overview
Standing up suddenly lowers blood pressure, a symptom of the uncommon autonomic nervous system disease known as neurogenic orthostatic hypotension (NOH). There is a minimal number of authorized therapies available, and the market for NOH is modest. Geographically speaking, the developed world’s leading markets for NOH products include those in North America, Europe, and Japan, where the aging population has led to a higher incidence of the condition. The biggest market for NOH is the US, followed by Europe and Japan. New medications have been introduced onto the market as a result of the increasing attention on developing treatments for NOH in recent years. In the NOH market, some of the leading companies include Lundbeck, Northera, and Droxidopa.
In general, it is anticipated that as more patients receive diagnoses and as novel therapies are created and authorized, the NOH market will expand during the next several years. However, compared to other therapeutic areas, the market is expected to remain relatively modest due to the disease’s rarity and the small number of patients.
Competitive Analysis
One kind of orthostatic hypotension brought on by autonomic nervous system malfunction is known as neurogenic orthostatic hypotension (NOH). In the US, it affects between 200,000 and 300,000 persons, making it a very uncommon ailment. As of right now, the FDA has only authorized a few medications to treat NOH, including pyridostigmine, droxidopa, and midodrine. Although the market for NOH treatments is still modest, it is expanding as more people become aware of the illness and as new therapies are created.
Reason to Buy this Report
- Industry research: This study offers information on market trends, prospects for development, and levels of competition. Businesses and investors may have a better grasp of the industry they are thinking about joining or operating in by reading a technology report. This will allow them to make more educated decisions based on facts and research.
- Competitive analysis: The study gives companies detailed knowledge about the advantages, disadvantages, and tactics of their rivals. With this knowledge, they might be able to recognize possible threats and market opportunities.
- Innovation: Businesses may keep informed about the most recent advancements and allocate resources wisely by leveraging the report’s insights on emerging technologies and trends.
- Due diligence: When contemplating an investment in the acquisition of a technology business, acquirers and investors may utilize the report as a component of their due diligence procedure. These studies can offer useful details on the company’s technology, its place in the market, and other important aspects.
Buy Now Neurogenic Orthostatic Hypotension (NOH) Market Report – https://wemarketresearch.com/purchase/neurogenic-orthostatic-hypotension-noh-market/1029?license=single
About We Market Research
We Market Research is a well-established market analytics and research organization with a diverse range of industry experience. We have been working on multi-county market research since our start. Throughout our history, we have earned accolades for our thorough market research and analytical analysis of many industry segments.
Our strategic market analysis and ability to appreciate the profound cultural, philosophical, and sociological components of many complex markets have helped us establish a name for ourselves in the business. We Market Research is a market leader in assisting several regional and worldwide firms in effectively achieving their business objectives via our in-depth market analysis. Furthermore, we may develop market strategies that ensure our clients have a consistent consumer base.
Contact Us
Mr. Robbin Joseph
Corporate Sales, USA
We Market Research
USA: +1-724-618-3925
Websites: https://wemarketresearch.com/
Email: [email protected]
